Tuesday, September 21, 2010

Cannabis: Potent Anti-Depressant In Low Doses, Worsens Depression At High Doses

Science News
Share Blog Cite
Print Email Bookmark
Cannabis: Potent Anti-Depressant In Low Doses, Worsens Depression At High Doses

ScienceDaily (Oct. 24, 2007) — A new neurobiological study has found that a synthetic form of THC, the active ingredient in cannabis, is an effective anti-depressant at low doses. However, at higher doses, the effect reverses itself and can actually worsen depression and other psychiatric conditions like psychosis.
See Also:
Health & Medicine

* Mental Health Research
* Controlled Substances

Mind & Brain

* Depression
* Marijuana

Plants & Animals

* Mice
* Virology


* Serotonin
* Psychopharmacology
* Seasonal affective disorder
* Psychedelic drug

It has been known for many years that depletion of the neurotransmitter serotonin in the brain leads to depression, so SSRI-class anti-depressants like Prozac and Celexa work by enhancing the available concentration of serotonin in the brain. However, this study offers the first evidence that cannabis can also increase serotonin, at least at lower doses.

Laboratory animals were injected with the synthetic cannabinoid WIN55,212-2 and then tested with the Forced Swim test -- a test to measure "depression" in animals; the researchers observed an antidepressant effect of cannabinoids paralleled by an increased activity in the neurons that produce serotonin. However, increasing the cannabinoid dose beyond a set point completely undid the benefits, said Dr. Gabriella Gobbi of McGill University.

"Low doses had a potent anti-depressant effect, but when we increased the dose, the serotonin in the rats' brains actually dropped below the level of those in the control group. So we actually demonstrated a double effect: At low doses it increases serotonin, but at higher doses the effect is devastating, completely reversed."

The anti-depressant and intoxicating effects of cannabis are due to its chemical similarity to natural substances in the brain known as "endo-cannabinoids," which are released under conditions of high stress or pain, explained Dr. Gobbi. They interact with the brain through structures called cannabinoid CB1 receptors. This study demonstrates for the first time that these receptors have a direct effect on the cells producing serotonin, which is a neurotransmitter that regulates the mood.

Dr. Gobbi and her colleagues were prompted to explore cannabis' potential as an anti-depressant through anecdotal clinical evidence, she said. "As a psychiatrist, I noticed that several of my patients suffering from depression used to smoke cannabis. And in the scientific literature, we had some evidence that people treated with cannabis for multiple sclerosis or AIDS showed a big improvement in mood disorders. But there were no laboratory studies demonstrating the anti-depressant mechanism of action of cannabis."

Because controlling the dosage of natural cannabis is difficult -- particularly when it is smoked in the form of marijuana joints -- there are perils associated with using it directly as an anti-depressant.

"Excessive cannabis use in people with depression poses high risk of psychosis," said Dr. Gobbi. Instead, she and her colleagues are focusing their research on a new class of drugs which enhance the effects of the brain's natural endo-cannabinoids.

"We know that it's entirely possible to produce drugs which will enhance endo-cannabinoids for the treatment of pain, depression and anxiety," she said.

The study, published in the October 24 issue of The Journal of Neuroscience, was led by Dr. Gabriella Gobbi of McGill University and Le Centre de Recherche Fernand Seguin of Hôpital Louis-H. Lafontaine, affiliated with l'Université de Montréal. First author is Dr. Gobbi's McGill PhD student Francis Bambico, along with Noam Katz and the late Dr. Guy Debonnel* of McGill's Department of Psychiatry.
Email or share this story:
| More

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by McGill University, via EurekAlert!, a service of AAAS.

Need to cite this story in your essay, paper, or report? Use one of the following formats:

McGill University (2007, October 24). Cannabis: Potent Anti-depressant In Low Doses, Worsens Depression At High Doses. ScienceDaily. Retrieved September 21, 2010, from http://www.sciencedaily.com­ /releases/2007/10/071023183937.htm

Note: If no author is given, the source is cited instead.

At higher doses, THC, the active ingredient in cannabis, can actually worsen depression and other psychiatric conditions like psychosis, a new study has found. (Credit: iStockphoto/Julie Masson Deshaies)
Ads by Google
Major Depressive Disorder
Physicians: Learn About An Adjunct
Therapy For MDD In Adult Patients.
Atrial Fibrillation Info
What is Atrial Fibrillation? Learn
More About AFib and Its Treatment.
Are You Depressed?
Our depression research study is
enrolling participants right now.
Type 1 Diabetes Research
Take Action. Learn About
Research to Protect Beta Cells
Related Stories
Smoked Medical Cannabis May Be Beneficial as Treatment for Chronic Neuropathic Pain, Study Suggests (Aug. 30, 2010) — The medicinal use of cannabis has been debated by clinicians, researchers, legislators and the public at large for many years as an alternative to standard pharmaceutical treatments for pain, which ... > read more
Oral Cannabis Ineffective In Treating Acute Pain, Study Finds (June 25, 2008) — Oral cannabis (a form of medical marijuana) not only failed to alleviate certain types of pain in human volunteers but, surprisingly, it instead caused increased sensitivity to some forms of pain. ... > read more
New Antidepressant Drug Increases 'Brain's Own Cannabis' (Dec. 13, 2005) — Researchers have discovered a new drug that raises the level of endocannabinoids--the 'brain's own cannabis'--providing anti-depressant effects. The new research published in this week's Proceedings ... > read more
Cannabis Smoke Is Less Likely To Cause Cancer Than Tobacco Smoke (Oct. 19, 2005) — Cannabis smoke is not as carcinogenic as tobacco smoke. In a review article published today in Harm Reduction Journal, Dr. Melamede from the University of Colorado, Colorado Springs, USA, writes that ... > read more
Minimal Relationship Between Cannabis And Schizophrenia Or Psychosis, Suggested By New Study (Oct. 22, 2009) — Last year the UK government reclassified cannabis from a class C to a class B drug, partly out of concerns that cannabis, especially the more potent varieties, may increase the risk of schizophrenia ... > read more
Ads by Google
Drug Lawsuits in IL

No comments:

Post a Comment